---
title: "Infosys Limited Stock 12‑Month Price Target Cut to $12.84, Implies 20% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293763247.md"
description: "Infosys Limited's 12-month average price target has been cut to $12.89 from $13.58, based on estimates from 48 analysts. This implies approximately 21% upside from the July 23 closing price. Despite the downward revision in targets, which range from $9 to $16.67, the consensus rating remains 'Buy' across the 52 covering analysts."
datetime: "2026-07-24T13:20:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293763247.md)
  - [en](https://longbridge.com/en/news/293763247.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293763247.md)
generator: "portal-rs"
---

# Infosys Limited Stock 12‑Month Price Target Cut to $12.84, Implies 20% Upside

-   According to estimates from 48 analysts, Infosys Limited stock's average price target has fallen from $13.58 to $12.89, with forecasts ranging from $9 to $16.67 per share
-   Based on the Jul. 23 closing price, the updated target implies approximately 21% potential upside
-   Consensus rating remains at “Buy” across 52 covering analysts, with 26 Buys, 21 Holds and 5 Sells

Explore more price target data and ratings for Infosys Limited on the , and track all previous and future analyst recommendations for Infosys Limited in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [INFY.US](https://longbridge.com/en/quote/INFY.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [FOCUS-AI reshapes India's IT services sector contracts as clients demand more for less](https://longbridge.com/en/news/296543708.md)
- [Infosys expands multiyear IT services deal with Metsä Group to support AI-led operations transformation](https://longbridge.com/en/news/295066655.md)
- [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md)
- [Infosys Posts Q1 FY27 Revenue Gain and Strong AI-Led Deal Wins, Trims Full-Year Sales Outlook](https://longbridge.com/en/news/294095280.md)
- [Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside](https://longbridge.com/en/news/295819689.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**